5
bad5
2="" class="plug-padding-tb" style="padding: 60px 0px 14px;">5
, 49, 141); visibility: hidden;">5
" data-expr="item.date1" data-index="0" data-ckey="jso_M_Title1" data-key="items" style="border-bottom-color: rgb(25
5
, 25
5
, 25
5
); border-bottom-width: 0px;">5
5
" data-expr="item.desc" data-index="0" data-ckey="jso_Text" data-key="items" style="position: relative;">Huiyu Pharmaceuticals is an R&D-centric integrated pharmaceutical company, primarily focusing on the development and manufacture of anti-cancer drugs, aiming to develop innovative therapeutic drugs to transform cancer to chronic disease.
Mission
Improve patients’ lives by curing cancer a controllable disease and
fransforming cancer to chronic disease.
Vison
Become a world leading pharmaceutical company in developing and delivering high quality and cost-effective therapeutics to patients worldwide.
Core Value
Caring for life, pursuing excellence, simplicity, and integrity.
History
Huiyu Pharmaceutical was established
The company's founder, Dr. Zhao Ding , gave up development opportunities in Europe and returned to China to tackle the problem of cancer drug accessibility with full confidence and vision.He took "making cancer a controllable chronic disease" as his mission when he founded this company which is located in his hometown of Neijiang, Sichuan.
Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
The establishment of overseas subsidiaries is an important measure of internationalization. Huiyu firmly adheres to the original intention of the establishment of the enterprise - "serving the country with industry and revitalizing the hometown". In order to benchmark international high-quality drugs and promote the goal of international circulation, a series of forward-looking entrepreneurial initiatives have been launched.
2011_y3py.jpg?_t=563262" title="" alt="" class="slide_img">Huiyu Pharmaceutical fully launched R&D and production lines
Huiyu established its self-requirements of "high production quality" at the initial stage of production, and benchmarked domestic production levels against international requirements. Strictly control production and testing procedures to ensure stable product quality and lay a solid quality foundation for developing international markets.
2012.jpg?_t=562483" title="" alt="" class="slide_img">Huiyu Pharmaceutical vigorously acquire talents and procure advanced equipment
Under the deployment of Huiyu's international vision, the company began to formally set up its own R&D team. With Bole vision, Huiyu recruit top scientific research talents domestically and abroad. At the same time, for the development of international markets and drug registration and other business fields, Huiyu seek talent with eagerness and employ people according to their abilities.
Huiyu Irinotecan is approved for marketing in the United Kingdom
Huiyu achieved the first batch production of drug validation products.Irinotecan was approved for marketing in the UK, becoming the first Chinese self-owned pharmaceutical brand approved for marketing in the UK.
2013-2.jpg?_t=563261" title="" alt="" class="slide_img">Huiyu Pharmaceutical has passed the GMP certification in China and the UK
Huiyu Pharmaceutical has established a rigorous international quality management system according to the requirements of domestic and foreign regulations. In 2014
, the company passed the GMP certification of China and the GMP certification of the UK Food and Drug Authority (MHRA), becoming the first injection enterprise in China which passed the GMP certification of the UK.
Huiyu adheres to high standards of technology and research and development
Huiyu insists on carrying out efficient and professional technology transfer work. It not only cooperates with foreign DLRC consulting companies, but also hires foreign R&D experts to provide experience guidance, conduct R&D SOF sorting, and formulate the original "Huiyu Standard".
2014-2.jpg?_t=563262" title="" alt="" class="slide_img">Seacross Pharma obtained EU drug release qualification certification
Huiyu Pharmaceutical has always adhered to strict control of drug quality standards. With the efforts of the international QP Overo and its team, Huiyu's British subsidiary Seacross Pharma officially obtained the EU MIA product release qualification.The drugs continued to circulate internationally, achieving the first domestic self-owned high-end tumor injection sales in the UK.
Huiyu focuses on the national generic drug consistency evaluation strategy
In the process of technological exploration, Huiyu Pharmaceutical has always adhered to the tripartite research and development and drug quality standards, participated in the formulation of technical requirements for the consistency evaluation of generic drug injections organized by the State Food and Drug Administration, and contributed Huiyu's strength to the international promotion of Chinese drugs. After the introduction of "One of the imitation receiving units of Chemical Injection, Pharmaceutical consistency technical Requirements", Huiyu became the first enterprise to be reviewed.
Huiyu Pemetrexel disodium for injection became the first injection that passed the consistency evaluation in China
On November 28, 2017
, CDE issued the Notice on Publicly soliciting Opinions on the First batch of varieties included in the Catalogue of Listed Chemical Drugs in China. Among the many varieties, Sichuan Huiyu's Pemetrexide disodium for injection is particularly noteworthy, because it is the only nominated chemical generic drug for injection. And it was eventually included in the Catalogue of Listed Drugs in China.
On November 28, 2017
, CDE issued the "Notice on Public Solicitation of Opinions on the First Batch of Varieties Included in the Catalog of Chemical Drugs Listed in China". Among the many varieties, Sichuan Huiyu's Pemetrexed II for Injection Sodium deserves special attention because it is the only chemical generic drug nominated for injection and was eventually included in the "China Marketed Drug Catalog".
2017-2.jpg?_t=563263" title="" alt="" class="slide_img">Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
0Under the opportunity of vigorously promoting the reform of the national medical system, Huiyu Pharmaceutical actively responds to the national "three medical linkage" policy, and accepts the promotion of product price while insisting on high-quality output, solving the medical insurance control cost and clinical needs, and opening the domestic hospital market with an atmospheric pattern. In December 2018
, Pemetrexed disodium for "Haiyue" injection entered the "4+7" national volume procurement, and 11 cities were selected.
Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
1Huiyu has established four major research institutes to support the company's strategic layout of "combination of generics and innovations". The company has attracted a large number of cutting-edge academic talents in the fields of biomolecules, pharmacology, preparations and other fields from world-renowned universities, as well as well-known overseas pharmaceutical companies. Senior experts from the company are expanding the innovative drug research and development team. A core team composed of returned talents led the project team to carry out research and development, opening a new chapter in Huiyu innovation.
2019_dop2.jpg?_t=563263" title="" alt="" class="slide_img">Hai Yue won the UK's Best Cancer Injection award
GHP (Global Health & Pharma) is a global health and pharmaceutical information sharing platform that aims to enhance communication and collaboration across themes and disciplines within the three categories of human, animal and environmental health. The award recognizes the most outstanding companies, teams and individuals in the healthcare and pharmaceutical industry in 2019
. Seacross Pharmaceutical UK, a wholly-owned subsidiary of Huiyu Pharmaceutical, was awarded the award for its outstanding product quality and rapid business growth.
Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
3Huiyu Pharmaceutical achieved annual revenue of 1.36 billion RMB, becoming one of the only two domestic pharmaceutical industry companies to achieve double positive growth every year, and was called a "dark horse in the pharmaceutical industry" by the media. However, Huiyu is prepared for danger in times of peace, still adheres to high-quality and high-standard production, develops pragmatically, and devotes its work to innovative research and development.
2020_ee2a.jpg?_t=563263" title="" alt="" class="slide_img">Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
4On the road of rapid growth, Huiyu Pharmaceutical has been actively undertaking social responsibilities, promoting cleaner production, and establishing a cleaner production management system suitable for pharmaceutical enterprises. The construction of high standards has been recognized, and the company has been officially approved as the "fifth batch of national green factories" by the Ministry of Industry and Information Technology.
Multiple R & D and production bases of Huiyu were officially launched
In 2020
, Huiyu Innovative Drug Research Institute Base, EU Standard Injection Industrialization Base (Phase II), and Zeyu Pharmaceutical API and Preparation Production Base were officially launched. Huiyu has formed a layout of three major bases. The company is a comprehensive pharmaceutical company driven by research and development, and has an international and high-standard quality system in the production of APIs and high-end anti-tumor injections.
Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
6Since Huiyu was established in 2010
, in the past ten years, the company has laid a solid foundation through "foster innovation by generics ". In the next decade, the company will embark on a new journey of "combination of generics and innovation". In the third decade, The company will bravely climb to the peak of "innovation first".
Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
7The production line that passed the inspection this time is the production line of injection workshop (I). In addition to Docetaxel injection, the representative products of this production line also include pemetrexed disodium for injection and paclitaxel injection. Huiyu has passed the FDA certification, marking that the company's GMP management has reached a higher level. The company's production line conforms to the quality management system of China, the United States and Europe.
Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
8On the list of TOP100 Chinese chemical pharmaceutical Enterprises in 20111
, Huiyu Pharmaceutical was selected for the list ranking 53rd with its strong innovation ability and marketing ability. Compared with the TOP100 list of Chinese chemical pharmaceutical companies in 2020
, Huiyu Pharmaceutical's ranking has jumped 27 places in three years.
Huiyu Pharmaceutical UK subsidiary Seacross Pharmaceutical was established
9As of 20111
, there are 92 national enterprise technology centers in Sichuan Province, and 5 new enterprises in the province have been selected, and Huiyu Pharmaceutical is the only enterprise in Neijiang City that has been recognized. The recognition of the National enterprise technology Center is also the affirmation of Huiyu Pharmaceutical's high-level innovation ability by the state.
Innovative
Therapeutic
R&D
Generic Medicine
CDMO/CMO
Partnering
Investors
Contact Us
